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ABSTRACT
A rapid and simple HPLC method was developed for the determination of xanthonolol concentration in plasma. The sample preparation utilized liquid-liquid extraction before injection into the HPLC system. Phenazine was used as the internal standard. Separation
was obtained using a reversed-phase column under isocratic conditions. The mobile phase consisted of a 65% McIlvaine buffer containing 0.05% triethylamine adjusted to pH 6.4 with phosphoric acid, 18% acetonitrile, and 17% methanol. Xanthonolol was detected
at the ultraviolet wavelength 235 nm. The lower limit of quantization was 50 ng/mL. The assay was applied to a pharmacokinetic
study in rats. The plasma concentration of xanthonolol versus time data were best fitted to a two-compartment open model with firstorder elimination processes. After the intravenous administration of xanthonolol at three different dosages of 5, 10 and 15 mg/kg, the
respective pharmacokinetic parameters, such as apparent volume of distribution, half-life, and clearance, showed no significant difference at three different dosages. Also, the area under the plasma concentration time curves for three dosages increased proportionally
with dose. Therefore, the pharmacokinetics of xanthonolol was found to be linear over the dose range studied.
Key words: xanthonolol, HPLC method, pharmacokinetics

INTRODUCTION
Xanthonoids are a group of natural substances, which
are widely distributed in the families Gentianaceae and
Guttiferae. Among their various biological properties, they
have been shown to be potent as inhibitors of platelet aggregation and as vasorelaxing agents (1,2) . Particularly,
researchers suggested the inhibitory effect on the contractile
response caused by high potassium ion and norepinephrine
in rat thoracic aorta of norathyriol, a 1,3,6,7-tetrahydroxy
xanthone obtained from Gentianaceae, was mainly due to
the inhibition of the calcium ion influx through both voltagedependent and receptor-operated calcium channels(2). A
series of xanthonoxypropanolamine-related compounds,
flavonoxy- propanolamines, have been shown to exist antihypertensive activity in spontaneously hypertensive rats(3).
Since propanolamine is chemically one of a key group of
beta adrenoceptor blockers and since xanthones may possess
calcium ion blocking-dependently hypotensive effect, xanthonolol, a derivative of 3-hydroxyxanthone (Figure 1), was
synthesized and tested for its possible beta adrenergic and
calcium channel blocking and vasodilating activities(4-7).
Very little study has been done on pharmacokinetic and its
effects in animals. According to the other research about the
similar structural compound (5,6-dimethyl-xanthenone-4acetic acid, DMXAA), satisfactorily fitted to a two-compartment model with capacity-limited kinetics in the mouse and
rat(8,9). The capacity-limited elimination of DMXAA exhibited a disproportionate increase in AUC with increasing
dose. Hence, we administered the different dosages of xan* Author for correspondence. Tel: 886-7-3121101 ext. 2261;
Fax: 886-7-3210683; E-mail: yabihu@kmu.edu.tw
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Figure 1. Structure of xanthonolol.

thonolol to evaluate the pharmacokinetic model in rat.
Quantitative analyses of the xanthone and its derivatives have been performed by HPLC (8,10) . From the
previous study, the linearity over the concentration range
used for the analysis of xanthone and 3-methoxyxanthone
in nanocapsule formulations was not sensitive enough for
the plasma specimen by UV detector. DMXAA was
analyzed by HPLC using fluorescence detection. In the
present study, we have developed a specific, accurate and
reproducible HPLC method using UV detection to
determine the concentration of xanthonolol in rat plasma
and examined the pharmacokinetic profile of xanthonolol in
rats to establish a drug administration regimen applicable
for clinical trial.

MATERIALS AND METHODS
I. Reagents and Materials
Xanthonolol was synthesized in the laboratory of pharmaceutical chemistry (Kaohsiung Medical University,
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Taiwan). Identification of the compound was established
by means of the spectral data (IR and NMR) (6) . The
internal standards phenazine, triethylamine, disodium
hydrogen phosphate dehydrate, and citric acid were
purchased from Merck (Germany). All other reagents were
analytical reagent grade. Methanol was obtained from
Fisher scientific (U.S.A.), acetonitrile was obtained from
Tedia Company (U.S.A.), and distilled water was purified
via Mill-Q reagent water system from Millipore (U.S.A.).
All other solvents used were of HPLC grade.
II. Instrumentation
A high performance liquid chromatographic (HPLC)
system consisted of Hitachi instruments equipped with a L7100 HPLC pump, an L-4000H UV detector (Hitachi,
Japan) wavelength at 235 nm, and a reversed-phase
Lichrosper 100 RP-18 column (5 µm, 125 × 4 mm i.d., E.
Merck, Germany). The mobile phase consisted of a 65%
McIlvaine buffer containing 0.05% triethylamine adjusted
to pH 6.4 with phosphoric acid, 18% acetonitrile, and 17%
methanol. The solution was filtered and degassed by
vacuum filtering through a 0.45-µm membrane filter. The
chromatography was preformed at room temperature and
the flow rate of the mobile phase was set at 1.0 mL/min.
The injection volume was 20 µL.
III. Drug Standards
Standard solutions of xanthonolol were prepared in
methanol at final concentrations ranging from 0.05 to 10
µg/mL. Plasma standards were prepared using drug-free rat
plasma spiked standard solution to obtain the appropriate
final concentrations. The internal standard solution (IS,
phenazine 5 µg/mL, 25 µL) was prepared in methanol.
IV. Drug Administration and Preparation of Plasma
Samples
The Wistar rats weighing about 200-250 g were used
in the pharmacokinetic study (Laboratory Animal Center of
National Science Council). These animals were divided
into three groups and administered 5, 10 and 15 mg/kg of
xanthonolol, respectively. Rats were anesthetized with pentobarbital (30 mg/kg) by intraperitoneal injection.
Xanthonolol solution prepared was administered via the tail
vein. Blood samples were drawn from the jugular artery at
0, 5, 15, 30, 60, 120, 180, 240, 360, 540 and 720 min after
xanthonolol administration. The blood samples were then
centrifuged at 3,000 rpm for 10 min. Plasma was immediately separated and stored at -20˚C until analysis.
V. Analytical Procedure and Assay Validation
Aliquots of blank, spiked or plasma samples (0.25 mL)
were added 25 µL of IS solution (5 µg phenazine/mL
methanol) and 5 mL of ethyl ether/n-hexane (2/1, v/v). The

mixture was horizontally shaken for 10 min and centrifuged
at 3,000 rpm for 10 min. The organic layer was transferred
to another tube and evaporated to dryness by vacuum
pump. The dry residue was reconstituted in 250 µL of
methanol and the clear supernatant was injected into the
HPLC system.
Standards of rat plasma were prepared and analyzed
during method validation. Linearity of standard curves,
intra- and inter-assay precision and accuracy were determined from these data. The limit of quantization (LOQ) of
xanthonolol was determined. LOQ is the smallest concentration where signals can be distinguished from the noise
level(11). The recovery of extraction was determined by the
peak area ratio from processed plasma sample to those from
xanthonolol standards in methanol solution for each
standard concentration.
VI. Analysis of Pharmacokinetic Data
Concentrations were analyzed using the PCNONLIN
computer program (V4.0, SCI software, U.S.A.) to
determine the type of compartment model using the correlation coefficient of observed and predicted data. The
following pharmacokinetic parameters were assessed: the
area under the plasma concentration-time curves from time
zero to infinity (AUC0∞ ), elimination rate constant (k),
half-life for the elimination phase (t1/2β), clearance (Cl), the
volume of distribution (Vdss) and the mean residence time
(MRT) were obtained. All data were expressed as mean ±
standard derivation. The AUC0∞ were calculated by the
trapezoidal rule (AUC0t) and extrapolated to time infinity
by the addition of AUC0∞ . The k value was the terminal
slope which was calculated by linear regression of the logarithmic value of the terminal phase. The Cl value was calculated as Dose/[AUC0∞ ], and the Vdss was obtained
from the summation of central and tissue compartments.
MRT was calculated from AUMC/AUC.

RESULTS AND DISCUSSION
The development of the HPLC method was initiated
due to the effect of certain variables including the selection
of organic phase, the concentration of the buffer, and the pH
of the mobile phase. According to the retention time, peak
height and peak asymmetry factor, the suitable conditions of
the mobile phase was established as follow consisting of a
65% McIlvaine buffer containing 0.05% triethylamine
adjusted to pH 6.4 with phosphoric acid, 18% acetonitrile,
and 17% methanol. The retention times for xanthonolol and
IS were 5.5 min and 15.0 min, respectively.
The chromatographic system was also applied to a
pharmacokinetic study. Hence, the extraction procedure
was an important step for the isolation of the analytes from
the rat plasma sample. After several trials, it was found
that the one-step liquid-liquid extraction of xanthonolol in
plasma was satisfactory. The extraction efficiencies of xan-
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Table 1. Precision and accuracy of intra- and inter-day validation in rats plasma
Expected
Intra-day
Concentration
Observed
Error
Precision
(µg/mL)
(mean ± SD)
(%)
(CV, %)
0.05
0.061 ± 0.001
21.4
1.65
0.1
0.112 ± 0.007
12.3
6.26
0.2
0.206 ± 0.004
3.2
1.68
0.5
0.484 ± 0.007
-3.2
1.39
1.0
0.969 ± 0.017
-3.1
1.72
2.0
2.018 ± 0.038
0.9
1.90

(A)

Inter-day
Error
(%)
37.6
9.7
6.0
-4.0
-4.7
1.4

Observed
(mean ± SD)
0.069 ± 0.004
0.110 ± 0.005
0.212 ± 0.003
0.480 ± 0.019
0.953 ± 0.039
2.027 ± 0.086

(B)

Precision
(CV, %)
6.40
4.72
1.61
4.04
4.04
4.22

(C)

(1)

(2)

(2)

(1)
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Figure 2. HPLC chromatograms of xanthonolol in rat plasma. A. blank plasma; B. (1) xanthonolol 0.05 µg/mL and (2) phenazine (IS, 0.5
µg/mL); C. (1) xanthonolol 1 µg/mL and (2) phenazine (IS, 0.5µg/mL).
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thonolol from plasma were determined for each standard
concentration from validation standards. The mean
recovery was 86.0% for rat plasma (n = 6). Therefore, the
extraction method was reproducible and suitable for the
analysis of plasma samples. Under the chromatographic
conditions described above; symmetrical and well resolved
peaks were obtained for xanthonolol and IS. Typical chromatograms of xanthonolol in rat plasma are shown in
Figure 2. No interfering peaks from endogenous plasma
substances were observed for drug-free plasma.
In this assay, xanthonolol in rat plasma could be
measured reliably over a wide range of concentration from
0.05 to 2.0 µg/mL using 0.25 mL of plasma samples. The
linearity between 0.05 and 2 µg/mL was determined using
the least-square linear regression with concentration and
peak area ratio. The regression equation was y = 0.8189x –
0.0366 (R2 = 0.9988, n = 6), where y is the concentration of
xanthonolol in plasma, x is the peak area ratio, and R2 is the
determination coefficient. The LOQ for xanthonolol under
these conditions was 0.05 µg/mL.
The precision expressed as the coefficient of variation
(CV) was calculated for both inter- and intra-day for each
standard concentration. All data show the excellent reproducibility of the sample analysis. The CV value was less
than 6.5% at 50 ng/mL and complied with the requirements
of assay validation. Accuracy was calculated as a relative
error (%) for each standard concentration. Results of

1.0
0.8
0.6
0.4
0.2
0.0
0

200

400

600

800

Time (min)

Figure 3. Plasma concentration-time curves of xanthonolol after
intravenous administration at doses of 5, 10 and 15 mg/kg in rats
(mean ± SD).

precision and accuracy for rat plasma are shown in Table 1.
The analyticl procedure described here was applied to
determine xanthonolol in plasma samples of rats from a
pharmacokinetic study. After intravenous administrations
of 5, 10, and 15 mg/kg xanthonolol, the plasma level of the
drug declined with time in a biphasic pattern as shown in
Figure 3. The plasma concentration of xanthonolol versus
time data were best fitted by a two-compartment open
model with first-order elimination processes. The initial
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Table 2. Pharmacokinetic parameters of xanthonolol after intravenous administration at doses of 5, 10 and 15 mg/kg in rats (mean ± SD)
Parameters
5 mg/kg (n = 6)
10 mg/kg (n = 5)
15 mg/kg (n = 3)
107.44 ± 24.99
189.67 ± 80.37
346.65 ± 49.31
AUC0∞ (µg • min/mL)
437.16 ± 120.60
421.19 ± 121.17
447.98 ± 130.57
t1/2β (min)
5.75 ± 1.45
7.29 ± 1.33
6.84 ± 1.40
Vss (L)
Cl (mL/min)
9.78 ± 2.48
13.11 ± 4.97
10.97 ± 1.60
MRT (min)
599.49 ± 148.21
597.30 ± 173.05
638.01 ± 180.66

CONCLUSION
This was a rapid, sensitive, selective and reliable
HPLC method for the quantitative determination of a derivative of 3-hydroxyxanthone, xanthonolol, and has been successfully used in plasma samples for a pharmacokinetic
study. The plasma concentration of xanthonolol versus
time data were best fitted to a two-compartment open
model with first-order elimination processes and following
linear pharmacokinetics.
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